AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth
- Funding enables AMSilk to scale industrial production and meet global customer demand for biotech produced silk-based protein materials
- The financing round was led by existing investor ATHOS (AT Newtec), with strong participation from fellow existing investors MIG Capital and Novo Holdings
- The total EUR 52M includes EUR 30M in cash and EUR 22M in convertible equity
Neuried, Germany, September 9, 2025 – AMSilk GmbH (“AMSilk”), a frontrunner in advanced biomaterials made from silk-based proteins, today announced it has successfully secured EUR 52 million financing led by existing investor ATHOS (AT Newtec), along with strong participation from fellow existing investors MIG Capital and Novo Holdings. The financing combines EUR 30 million in equity, and EUR 22 million in convertible bonds. This reflects strong investor confidence and long-term commitment in AMSilk’s technology and market potential.
